Dupixent (dupilumab) is a **non-preferred** product and will only be considered for coverage under the **pharmacy** benefit when the following criteria are met:

Members must be clinically diagnosed with one of the following disease states and meet their individual criteria as stated.

**MODERATE-TO-SEVERE ATOPIC DERMATITIS**

For **initial** authorization:
1. Member must be 18 years of age or older; AND
2. Medication must be prescribed by a dermatologist, allergist or immunologist; AND
3. Member’s atopic dermatitis involving 10% or more of the body surface area (BSA); AND
4. Documented member’s Eczema Area and Severity Index (EASI) score is ≥16 (on a scale of 0-72) submitted with chart notes; AND
5. Member has documented trial and failure of or contraindication to at least **two** medium potency to very-high potency topical corticosteroids (e.g. Elocon (mometasone furoate), Synalar (fluocinolone acetonide), Lixid (flucinonide)); AND
6. Member has tried and failed to respond to phototherapy treatment (i.e. UV-A, UV-B, a combination of both, psoralen plus UV-A (PUVA), or UV-B1 (narrow-band UV-B)) for at least 12 weeks; AND
7. Member has documented trial and failure of or contraindication to at least **one** oral immunomodulatory agent (cyclosporine, methotrexate, azathioprine, or mycophenolate mofetil); AND
8. Member has documented trial and failure of or contraindication to both topical calcineurin inhibitors: Elidel (pimecrolimus) and Protopic (tacrolimus)); AND
9. Member is not receiving Dupixent in combination with another biologic medication for the treatment of atopic dermatitis (e.g. Xolair (omalizumab), Rituxan (rituximab), Enbrel (etanercept), Remicade/Inflectra (infliximab)).
10. **Dosage allowed:** Initial dose of 600 mg (two 300 mg injections in different injection sites), followed by 300 mg given every other week.

**If member meets all the requirements listed above, the medication will be approved for 6 months.**

For **reauthorization**:
1. Member must be in compliance with all other initial criteria; AND
2. Documented member’s EASI score improvement; AND
3. Member is not receiving Dupixent in combination with another biologic medication for the treatment of atopic dermatitis (e.g. Xolair (omalizumab), Rituxan (rituximab), Enbrel (etanercept), Remicade/Inflectra (infliximab)).

**If member meets all the reauthorization requirements above, the medication will be approved for an additional 6 months.**
CareSource considers Dupixent (dupilumab) not medically necessary for the treatment of the following disease states based on a lack of robust clinical controlled trials showing superior efficacy compared to currently available treatments:

- Scabies
- Seborrheic dermatitis
- Contact dermatitis (irritant or allergic)
- Ichthyoses
- Cutaneous T-cell lymphoma
- Psoriasis
- Photosensitivity dermatosis
- Immune deficiency diseases
- Erythroderma of other causes

<table>
<thead>
<tr>
<th>DATE</th>
<th>ACTION/DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/12/2017</td>
<td>New policy for Dupixent created.</td>
</tr>
</tbody>
</table>

References:

Effective date: 08/09/2017
Revised date: 06/12/2017